Opel, Daniela <br/><br/>
Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  May 2011 
 - 3233-47 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-10-2530  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Brain Neoplasms--drug therapy<br/>Chick Embryo<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Enzyme Activation--genetics<br/>Furans--administration & dosage<br/>Humans<br/>Mice<br/>Molecular Targeted Therapy<br/>Mutation--physiology<br/>Neuroblastoma--drug therapy<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Pyridines--administration & dosage<br/>Pyrimidines--administration & dosage<br/>TNF-Related Apoptosis-Inducing Ligand--administration & dosage<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays